ID consultation is needed for the use of baricitinib for Covid-19
In rare circumstances, baricitinib can also be considered alone when dexamethasone cannot be used
For children with severe or critical illness, use of baricitinib should be evaluated on a case-by-case basis in consultation with the Pediatric Infectious Diseases team
Baricitinib has been shown to reduce mortality among patients who are not undergoing mechanical ventilation
Baricitinib can be considered in combination with dexamethasone in certain hospitalized patients who are exhibiting rapid respiratory decompensation due to COVID-19 meeting the following inclusion/exclusion criteria below:
Admitted to ICU < 24 hours and:
OR
Recently hospitalized patients (not in an ICU) with:
Without high suspicion of bacterial/fungal/mycobacterial infection
4mg po daily for maximum of 14 days
eGFR ≥30 mL/min to <60 mL/min: Dose reduction to 2 mg PO daily
eGFR 15 mL/min to <30 mL/min: Dose reduction to 1 mg PO daily
eGFR <15 mL/min: Baricitinib is NOT recommended
Potential Therapeutic Agents